| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
PARSIPPANY, N.J.—In mid-October, Interpace Diagnostics Group Inc. presented new data at the 88th Annual Meeting of the American Thyroid Association (ATA) that support its molecular tests for thyroid cancer. The new interim data, spanning over 300 samples from a two-year “real world” retrospective study, highlighted the clinical utility of Interpace’s ThyGenX thyroid oncogene panel in combination with its micro-RNA classifier, ThyraMIR.
 
Nine centers from across the United States participated in this study, and the data reportedly demonstrated that ThyGenX/ThyraMIR combination test results help avoid unnecessary surgical resections and identify nodules where surgery is appropriate in cytologically indeterminate thyroid nodules. Importantly, the study also indicated that surgical decisions made based on the combination test results were appropriately aligned with risk of malignancy over clinical follow-up consistent with a combination test that effectively rules in and rules out higher risk of malignancy.
 
Recently, Interpace launched an expanded mutation panel called ThyGeNEXT, which includes additional markers such as TERT, PTEN, ALK and RET among others. As the company’s Clinical Experience Study progresses, patients tested with ThyGeNEXT will also be included to demonstrate the clinical utility of the latest version of the product.

Related Topics

Published In

Volume 14 - Issue 12 | December 2018

December 2018

December 2018 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue